Skip to main content
Premium Trial:

Request an Annual Quote

FDA Grants EUA for Scope Molecular Laboratory SARS-CoV-2 Test for Serial Testing

NEW YORK — The US Food and Drug Administration recently granted Emergency Use Authorization for Scope Molecular Laboratory's SARS nCoV-2019 Multiplexed Assay for serial COVID-19 testing.

The laboratory-developed test uses RT-PCR to detect SARS-CoV-2 RNA in anterior nasal swab specimens either collected by a healthcare provider or self-collected under the supervision of a healthcare provider. It may only be performed by Sublimity, Oregon-based Scope Molecular Laboratory, according to the FDA.

The test received authorization as an umbrella EUA for serial testing, which allows authorized tests to be used with individual or pooled specimens to test people at least once per week regardless of symptoms or exposure to COVID-19, such as in serial testing programs implemented by schools or workplaces.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.